IP Library › Granted Patent US 12,533,407
Granted Patent B2
US 12,533,407 · App. 17/497,439 · Granted Jan 27, 2026

Methods of selecting T cell line and donor thereof for adoptive cellular therapy

Inventors: Richard J. O'Reilly (Roxbury, CT); Ekaterina Doubrovina (Bronx, NY); Guenther Koehne (New York, NY); Aisha N. Hasan (Blue Bell, PA); Susan E. Prockop (New York, NY)
Assignee: Memorial Sloan Kettering Cancer Center
A61K39/25A61K40/11A61K40/46C12Q1/6881G01N33/505G01N33/574G01N33/57407G16B35/00G16B35/20G16B45/00G16C20/60A61K2039/572C12Q2600/136C12Q2600/172G01N2333/03G01N2333/045G01N2333/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,533,407
App. No.
17/497,439
Granted
Jan 27, 2026
Kind
B2
Abstract

Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer.

Claims (31)

1 . A method of treating a human patient having or suspected of having (i) a pathogen that is cytomegalovirus (CMV) and symptoms of an infection by the pathogen or (ii) a cancer that is an Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disorder, comprising:

(a) selecting an allogeneic T cell line for therapeutic administration to the patient according to a method comprising:

selecting a T cell line allogeneic to the patient that recognizes at least one epitope of an antigen of the pathogen or the cancer, using a representation that (i) identifies a plurality of HLA alleles and optionally HLA allele combinations, and (ii) discloses indications of relative activities of T cell lines, each recognizing at least one epitope of an antigen of the pathogen or cancer, and restricted to different ones of the HLA alleles or HLA allele combinations in the plurality; wherein in the representation each identified HLA allele or HLA allele combination is associated with the respective indication of relative activity of the T cell line restricted to the HLA allele or HLA allele combination, the relative activities being relative measures of known activity against the pathogen or against the cancer exhibited by the T cell lines, wherein the relative activities are in vivo clinical efficacies of the T cell lines in treatment of human patients having the pathogen or cancer, wherein each indication of relative activity is based on clinical data from a population of human patients; wherein

(A) the T cell line selected has in common with the patient or diseased cells in the patient the HLA allele or HLA allele combination identified by the representation to which the recognition of the T cell line is restricted; and

(B) the HLA allele or HLA allele combination, to which the T cell line selected is restricted, is associated in the representation with an indication of the highest relative activity among the HLA alleles and HLA allele combinations in the representation that are known to be in common with the patient or the diseased cells in the patient and are not otherwise disqualified;

(b) generating the representation prior to the selecting step;

(c) measuring the relative activities prior to the generating step; and

(d) administering a population of T cells derived from the selected allogeneic T cell line to the patient.

2 . The method of claim 1 , wherein the representation is a list of the plurality of HLA alleles and optionally HLA allele combinations ranked by the relative activities.

3 . The method of claim 1 , wherein the representation is a database listing the plurality of HLA alleles and optionally HLA allele combinations, each associated with a score indicative of relative activity.

4 . The method of claim 1 , wherein the patient has or is suspected of having a pathogen that is CMV and symptoms of an infection by the pathogen, wherein the T cell lines recognize at least one epitope of an antigen of the pathogen, and wherein the relative activities are relative measures of known activity against the pathogen.

5 . The method of claim 1 , wherein the patient has or is suspected of having a cancer that is an EBV-positive post-transplant lymphoproliferative disorder, wherein the T cell line recognizes at least one epitope of an antigen of the cancer, and wherein the relative activities are relative measures of known activity against the cancer.

6 . A method of treating a human patient having or suspected of having (i) a pathogen that is CMV and symptoms of an infection by the pathogen or (ii) a cancer that is an EBV-positive post-transplant lymphoproliferative disorder, comprising:

(a) selecting an allogeneic T cell line for therapeutic administration to the patient according to a method comprising:

selecting a T cell line allogeneic to the patient that recognizes at least one epitope of an antigen of the pathogen or the cancer, using a representation that (i) identifies a plurality of HLA alleles and optionally HLA allele combinations, and (ii) discloses indications of relative activities of T cell lines, each recognizing at least one epitope of an antigen of the pathogen or cancer, and restricted to different ones of the HLA alleles or HLA allele combinations in the plurality; wherein in the representation each identified HLA allele or HLA allele combination is associated with the respective indication of relative activity of the T cell line restricted to the HLA allele or HLA allele combination, the relative activities being relative measures of known activity against the pathogen or against the cancer exhibited by the T cell lines, wherein the relative activities are in vivo clinical efficacies of the T cell lines in treatment of human patients having the pathogen or cancer, wherein each indication of relative activity is based on clinical data from a population of human patients;

wherein the representation has been determined by a process comprising generating the representation prior to the selecting step, and measuring the relative activities prior to the generating step; wherein

(A) the T cell line selected has in common with the patient or diseased cells in the patient the HLA allele or HLA allele combination identified by the representation to which the recognition of the T cell line is restricted; and

(B) the HLA allele or HLA allele combination, to which the T cell line selected is restricted, is associated in the representation with an indication of the highest relative activity among the HLA alleles and HLA allele combinations in the representation that are known to be in common with the patient or the diseased cells in the patient and are not otherwise disqualified; and

(b) administering a population of T cells derived from the selected allogeneic T cell line to the patient.

7 . The method of claim 6 , wherein the representation is a list of the plurality of HLA alleles and optionally HLA allele combinations ranked by the relative activities.

8 . The method of claim 6 , wherein the representation is a database listing the plurality of HLA alleles and optionally HLA allele combinations, each associated with a score indicative of relative activity.

9 . The method of claim 6 , wherein the patient has or is suspected of having a pathogen that is CMV and symptoms of an infection by the pathogen, wherein the T cell lines recognize at least one epitope of an antigen of the pathogen, and wherein the relative activities are relative measures of known activity against the pathogen.

10 . The method of claim 6 , wherein the patient has or is suspected of having a cancer that is an EBV-positive post-transplant lymphoproliferative disorder, wherein the T cell line recognizes at least one epitope of an antigen of the cancer, and wherein the relative activities are relative measures of known activity against the cancer.

11 . The method of claim 4 , wherein the representation is a list of the plurality of HLA alleles and optionally HLA allele combinations ranked by the relative activities.

12 . The method of claim 4 , wherein the representation is a database listing the plurality of HLA alleles and optionally HLA allele combinations, each associated with a score indicative of relative activity.

13 . The method of claim 5 , wherein the representation is a list of the plurality of HLA alleles and optionally HLA allele combinations ranked by the relative activities.

14 . The method of claim 5 , wherein the representation is a database listing the plurality of HLA alleles and optionally HLA allele combinations, each associated with a score indicative of relative activity.

15 . The method of claim 9 , wherein the representation is a list of the plurality of HLA alleles and optionally HLA allele combinations ranked by the relative activities.

16 . The method of claim 9 , wherein the representation is a database listing the plurality of HLA alleles and optionally HLA allele combinations, each associated with a score indicative of relative activity.

17 . The method of claim 10 , wherein the representation is a list of the plurality of HLA alleles and optionally HLA allele combinations ranked by the relative activities.

18 . The method of claim 10 , wherein the representation is a database listing the plurality of HLA alleles and optionally HLA allele combinations, each associated with a score indicative of relative activity.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2022
From: O'REILLY, RICHARD J.; DOUBROVINA, EKATERINA; KOEHNE, GUENTHER; HASAN, AISHA N.; PROCKOP, SUSAN E.
To: MEMORIAL SLOAN KETTERING CANCER CENTER
Reel/Frame 058627/0459 →
Continuity (3)
Division 15523544
Provisional Application 62075856 · Nov 5, 2014
Related Publication 20220023417A1 · Jan 27, 2022
References Cited (118)
US 6723695B1 · Burrows et al. · 2004 [cited by applicant]
US 8425898B2 · Sampson et al. · 2013 [cited by applicant]
US 9011835B2 · Sampson et al. · 2015 [cited by applicant]
US 11173205B2 · O'Reilly et al. · 2021 [cited by applicant]
US 20040265325A1 · Diamond et al. · 2004 [cited by applicant]
US 20050181459A1 · Baker et al. · 2005 [cited by applicant]
US 20140086888A1 · Heslop et al. · 2014 [cited by applicant]
CL 199702140 · 1997 [cited by applicant]
CL 199802108 · 1998 [cited by applicant]
CL 199802417 · 1998 [cited by applicant]
CL 201701110 · 2018 [cited by applicant]
EP 3215165B1 · 2020 [cited by applicant]
JP 2013541332 · 2013 [cited by applicant]
RU 2003127388 · 2005 [cited by applicant]
WO WO1996029394 · 1996 [cited by applicant]
WO WO1998016238 · 1998 [cited by applicant]
WO WO1999018981 · 1999 [cited by applicant]
WO WO2002069232 · 2002 [cited by applicant]
WO WO2011017151 · 2011 [cited by applicant]
WO WO2012038055 · 2012 [cited by applicant]
WO WO2014150924 · 2014 [cited by applicant]
WO WO2016073550 · 2016 [cited by applicant]
WO WO2019178170 · 2019 [cited by applicant]
Cole et al (Int. Immunol. 1994, 6(11): 1767-1775) (Year: 1994). [cited by examiner]
HLA Nomenclature, 2023, 2 pages) (Year: 2023). [cited by examiner]
Beatty and Gladney (Clin. Canc. Res. 2014, 21(4): 687-692) (Year: 2014). [cited by examiner]
Kerkar and Restifo (Cancer Res. 2012, 72(13): 3125-3130) (Year: 2012). [cited by examiner]
Schumacher and Schreiber (Science, 2015, 348: 69-74) (Year: 2015). [cited by examiner]
Ali-Khan et al (Curr. Prot. Protein Sci. 2002, 22.1.1-22.1.19, Suppl. 30, John Wiley & Sons, Inc.) (Year: 2002). [cited by examiner]
He et al (Virology, 2025, 604, 110445, 10 pages) (Year: 2025). [cited by examiner]
Balduzzi et al., Jul. 2011, “Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient,” Bone Marrow Transplantation, 46(7):987-992. [cited by applicant]
Bao et al., Apr. 2012, “Adoptive immunotherapy with CMV specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections,” Journal of Immunotherapy, 35(3):293-298. [cited by applicant]
Blyth et al., Nov. 2011, “BK virus-specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses,” Transplantation, 92(10):1077-1084. [cited by applicant]
Burns and Crawford, Sep. 2004, “Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease,” Blood Reviews, 18(3):193-209. [cited by applicant]
Cortivo et al., Nov. 2012, “Anti CMV and/or anti adenovirus IFN-g-positive CD4+ CD8+ T lymphocytes for treatment of viral infections after allogeneic HSC transplantation: first results,” Blood, 120(21):1906. [cited by applicant]
Einsele et al., Jun. 2002, “Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy,” Blood, 99(11):3916-3922. [cited by applicant]
Eiz-Vesper et al., Jan. 2013, “Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry,” Frontiers in Immunology, 3:410. [cited by applicant]
Feuchtinger et al., Nov. 2010, “Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantatio… [cited by applicant]
Gahn et al., Jan. 2002, “Immunotherapy to reconstitute immunity to DNA viruses,” Seminars in Hematology, 39(1):41-47. [cited by applicant]
Gerdemann et al., Jan. 2013, “Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation,” Blood, 121(1):207-218. [cited by applicant]
Haque et al., Oct. 2011, “Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells,” Transplantation, 72(8):1399-1402. [cited by applicant]
Haque et al., Aug. 2007, “Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial,” Blood, 110(4):1123-1131 (Published online… [cited by applicant]
Haque et al., Aug. 2002, “Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells,” Lancet, 360(9331):436-442. [cited by applicant]
Holmes-Liew et al., Mar. 2015, “Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation,” Clinical & Translational Immunology, 4(3):e35. [cited by applicant]
Kawakami et al., Oct. 2005, “A case of immune recovery vitritis induced by donor leukocyte infusion for the treatment of cytomegalovirus retinitis,” European Journal of Haematology, 75(4):352-354. [cited by applicant]
Leen et al., Jun. 2013, “Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation,” Blood, 121(26):5113-5123 (Published online Apr. 22… [cited by applicant]
Leen et al., Oct. 2006, “Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals,” Nature Medicine, 12(10):1160-1166 (Published onl… [cited by applicant]
Louis et al., Nov.-Dec. 2010, “Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma,” Journal of Immunotherapy, 33(9):983-990. [cited by applicant]
Papadopoulou et al., Jun. 2014, “Activity of broad-spectrum T cells as treatment for adv, ebv, cmv, bkv, and HHV6 infections after HSCT,” Science Translational Medicine, 6(242):242ra83. [cited by applicant]
Qasim et al., May 2013, “Interferon-γ capture T cell therapy for persistent Adenoviraemia following allogeneic haematopoietic stem cell transplantation,” British Journal of Haematology, 161(3):449-452 (Published online … [cited by applicant]
Ramos et al., Jan. 2013, “Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies,” Journal of Immunotherapy, 36(1):66-76. [cited by applicant]
Sili et al., Jan. 2012, “Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hemat… [cited by applicant]
Straathof et al., Mar. 2005, “Treatment of nasopharyngeal carcinoma with Epstein-Barr virus—specific T lymphocytes,” Blood, 105(5):1898-1904 (Published online Nov. 12, 2004). [cited by applicant]
Sukdolak et al., Oct. 2013, “CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome,” Biology of Blood and Marrow Transplantation, 1… [cited by applicant]
Uhlin et al., Oct. 2012, “Rapid salvage treatment with virus-specific T cells for therapy-resistant disease,” Clinical Infectious Diseases, 55(8):1064-1073 (Published online Jul. 17, 2012). [cited by applicant]
Waldrop et al., Apr. 1997, “Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency,” … [cited by applicant]
Walter et al., Oct. 1995, “Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor,” The New England Journal of Medicine, 333(16):1… [cited by applicant]
Wilkie et al., Jul.-Aug. 2004, “Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases,” Journal of Immunotherapy, 27(4):309-316. [cited by applicant]
Barker et al., Dec. 2010, “Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes,” Blood, 116(23):5045-5049 (Publishe… [cited by applicant]
Doubrovina et al., Nov. 2007, “Leukemia-reactive cytotoxic CD8+ and CD4+ T-cells specific for novel WT-1 epitopes are generated in vitro by sensitization with overlapping pentadecapeptides (15-mers) spanning the wilms t… [cited by applicant]
Doubrovina et al., Mar. 2012, “Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation,” Blood, 119(11):2644-2656 (Published on… [cited by applicant]
Doubrovina et al., Aug. 2012, “Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias,” Blood, 120(8):1633-1646… [cited by applicant]
Doubrovina et al., Nov. 2004, “In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity,” C… [cited by applicant]
Hasan et al., Dec. 2014, “Banked, GMP grade third party T-cell lines specific for CMVpp65 epitopes presented by certain prevalent HLA alleles more consistently clear CMV infections in a genetically heterogeneous populat… [cited by applicant]
Hasan et al., 2014, “Banked, GMP grade third party T-cell lines specific for CMVpp65 epitopes presented by certain prevalent HLA alleles more consistently clear CMV infections in a genetically heterogeneous population o… [cited by applicant]
Hasan et al., Feb. 2014, “Generation and characterization of a third party GMP grade bank of CMV specific T-cells for adoptive immunotherapy of CMV infections in recipients of HSCT from cord blood or seronegative donors… [cited by applicant]
Hasan et al., Nov. 15, 2013, “Generation and characterization of a third party GMP grade bank of CMV specific T-cells for adoptive immunotherapy of CMV infections in recipients of HSCT from cord blood or seronegative do… [cited by applicant]
Hasan et al., Aug. 2009, “A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy,” The Journal … [cited by applicant]
Koehne et al., Jul. 2000, “Rapid selection of antigen-specific T lymphocytes by retroviral transduction,” Blood, 96(1):109-117. [cited by applicant]
Koehne et al., Mar. 2002, “Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic p… [cited by applicant]
Prockop et al., Dec. 2014, “Third party donor derived CMV specific T cells for the treatment of refractory CMV viremia and disease after hematopoietic stem cell transplant,” Blood, 124(21):184, 2 pages. [cited by applicant]
Prockop et al., 2014, “Third party donor derived CMV specific T cells for the treatment of refractory CMV viremia and disease after hematopoietic stem cell transplant,” meeting abstract for the 56th American Society of … [cited by applicant]
Prockop et al., Feb. 2014, “Third party donor derived EBV specific T cells for the treatment of refractory EBV-related post-transplant lymphomas,” Biology of Blood and Marrow Transplantation, 20(2):S49-S50. [cited by applicant]
O'Reilly, meeting abstract for the oral presentation on Oct. 31, 2014 at The 76th Annual Meeting of the Japanese Society of Hematology, held Oct. 31-Nov. 2, 2014, Osaka, Japan, 1 page. [cited by applicant]
Trivedi et al., Apr. 2005, “Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy,” Blood, 105(7):2793-2801 (Published online Oct.… [cited by applicant]
O'Reilly et al., Sep. 2011, “Novel strategies for adoptive therapy following HLA disparate transplants,” Best Practice & Research Clinical Haematology, 24(3):381-391. [cited by applicant]
O'Reilly et al., May 2007, “Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants,” Immunologic Research, 38(1-3):237-250. [cited by applicant]
O'Reilly et al., Jun. 2010, “Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation,” Seminars in Immunology, 22(3):162-172 (Publ… [cited by applicant]
“Biological therapy in treating patients at high-risk or with lymphoma, lymphoproliferative disease, or malignancies,” ClinicalTrials.gov, accessed at https://clinicaltrials.gov/ct2/show/NCT00002663?term=NCT00002663&ran… [cited by applicant]
“Therapeutic effects of Epstein-Barr virus immune T-lymphocytes derived from a normal HLA-compatible or partially-matched third-party donor in the treatment of EBV lymphoproliferative disorders and EBV-associated malign… [cited by applicant]
“Primary transplant donor derived CMVpp65 specific T-cells for the treatment of CMV infection or persistent CMV viremia after allogeneic hematopoietic stem cell transplantation,” ClinicalTrials.gov, accessed at http://w… [cited by applicant]
“Trial of third party donor derived CMVpp65 specific T-cells for the treatment of CMV infection or persistent CMV viremia after allogeneic hematopoietic stem cell transplantation,” ClinicalTrials.gov, accessed at https:… [cited by applicant]
“Dose escalation trial of WT1-sensitized T cells for residual or relapsed leukemia after allogeneic hematopoietic progenitor cell transplantation,” ClinicalTrials.gov, accessed at https://clinicaltrials.gov/ct2/show/NCT… [cited by applicant]
“Busulfan, melphalan, fludarabine and T-cell depleted allogeneic hematopoietic stem cell transplantation followed by post transplantation donor lymphocyte infusions,” ClinicalTrials.gov, accessed at https://www.clinical… [cited by applicant]
“Dose escalation trial of WT-specific donor-derived T cells following -cell depleted allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory multiple myeloma,” ClinicalTrials.gov, access… [cited by applicant]
Prockop, “Adoptive immunotherapy with banked virus specific 3rd party donor T-cells for CMV infections and EBV LPD complicating hematopoietic cell transplants,” slide presentation on Oct. 31, 2014 at The 76th Annual Mee… [cited by applicant]
Prockop, “Third party donor T cells for the treatment of CMV infection and EBV lymphoma in immunodeficient patients,” slide presentation on May 22, 2014 at the 9th Meeting of the EBMT Pediatric Diseases WP, held May 21-… [cited by applicant]
Prockop, “3rd party CMV specific T cells for the treatment of refractory CMV viremia and disease after HSCT,” slide presentation on Dec. 7, 2014 at the 56th ASH Annual Meeting held Dec. 6-9, 2014, San Francisco, Califor… [cited by applicant]
Hasan, “Banked, GMP grade third party T-cell lines specific for CMVpp65 epitopes presented by certain prevalent HLA alleles more consistently clear CMV infections in a genetically heterogeneous population of HSCT recipi… [cited by applicant]
Prockop, “Third party donor derived EBV specific T cells for the treatment of refractory lymphoma in immunodeficient recipients,” slide presentation on Mar. 1, 2014 at the ASBMT 2014 BMT Tandem Meetings held Feb. 26-Mar… [cited by applicant]
Khanna et al., Aug. 1999, “Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease,” Proceedings of the Nation… [cited by applicant]
Comoli et al., Apr. 2002, “Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of acti… [cited by applicant]
Gandhi et al., May 2007, “Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders,” American Journal of Transplantation, 7(5):1293-1299 (Published online Apr. … [cited by applicant]
Lucas et al., Mar. 1996, “The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation,” Blood, 87(6):2594-2603. [cited by applicant]
Rooney et al., Sep. 1998, “Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients,” Blood, 92(5):1549-1555. [cited by applicant]
Schmitt et al., Mar. 2011, “Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell tr… [cited by applicant]
Micklethwaite et al., Jun. 2007, “Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation,” Biology of Blood and Marr… [cited by applicant]
Cobbold et al., Aug. 2005, “Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers,” The Journal of Experimental Medicine, 202(3):379-386. [cited by applicant]
Peggs et al., Oct. 2003, “Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines,” Lancet, 362(9393):1375-1377. [cited by applicant]
Latouch and Sadelain, Apr. 2000, “Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells,” Nature Biotechnology, 18:405-409. [cited by applicant]
Amarnath and Fowler, Jan. 2012, “Harnessing autophagy for adoptive T cell therapy,” Immunotherapy, 4(1):1-4. [cited by applicant]
Humar et al., Dec. 2009, “Cytomegalovirus in solid organ transplant recipients,” American Journal of Transplantation, 9(Suppl 4):S78-S86. [cited by applicant]
International Search Report, Information on Search Strategy, and Written Opinion of the International Searching Authority, for International Patent Application No. PCT/US2015/058939, mailed Feb. 10, 2016, 16 pages. [cited by applicant]
Saveanu et al., Oct. 2005, “Complexity, contradictions, and conundrums: studying post-proteasomal proteolysis in HLA class I antigen presentation,” Immunological Review 207:42-59. [cited by applicant]
Strehl et al., Oct. 2005, “Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing,” Immunological Review 207:19-30. [cited by applicant]
Sercarz et al., 1993, “Dominance and crypticity of T cell antigenic determinants,” Annual Review of Immunology, 11:729-766. [cited by applicant]
Yewdell and Bennink, 1999, “Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses,” Annual Review of Immunology, 17:51-88. [cited by applicant]
La Gruta et al., Jan. 2006, “A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies,” Proceedings of the National Academy of Sciences of the United States of America,… [cited by applicant]
Cole et al. , Nov. 1994, “The MHC class l-restricted T cell response to Sendai virus infection in C57BL/6 mice: a single immunodominant epitope elicits an extremely diverse repertoire of T cells,” International Immunolo… [cited by applicant]
Kast et al., Mar. 1991, “Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide,” Proceedings of the National Academy of Sciences of t… [cited by applicant]
Day et al., Jul. 2001, “Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles,” Journal of Virology, 75(14):6279-6291. [cited by applicant]
Yu et al., Sep. 2002, “Consistent Patterns in the Development and Immunodominance of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8+ T-Cell Responses following Acute HIV-1 Infection,” Journal of Virology, 76(1… [cited by applicant]
Lacey et al., Apr. 2003, “Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles,” Human Immunology 64(4):440-452. [cited by applicant]
Heslop et al., Feb. 2010, “Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients,” Blood, 115(5):925-935 (Published online Oct. 30, 2009). [cited by applicant]
Prockop et al., 2015, “Successful treatment of refractory CMV chorioretinitis and meningoencephalitis with adoptive transfer of third party CMVpp65 specific T-cell lines,” meeting abstract for the 57th American Society … [cited by applicant]
Rooney et al., Jan. 1995, “Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation,” Lancet, 345(8941):9-13. [cited by applicant]
Falkenburg et al., Sep. 2011, “Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity,” The Journal of Immunology 187(5):2824-2833. [cited by applicant]
HLA Nomenclature @ hla.alleles.org, “HLA Alleles Numbers assigned as of Jan. 2015,” accessed at: http://hla.alleles.org/nomenclature/stats.html, on Mar. 17, 2015, 2 pages. [cited by applicant]